Results 21 to 30 of about 756 (101)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation

Respiratory Medicine Case Reports, 2023
Eosinophilic granulomatosis with polyangiitis (EGPA) is systemic vasculitis caused by eosinophilia affecting small to medium-sized blood vessels, which damages the organs.
Mari Sato, Masakiyo Yatomi, Ikuo Wakamatsu, Shogo Uno, Chiharu Hanazato, Tomomi Masuda, Koichi Yamaguchi, Haruka Aoki-Saito, Norimitsu Kasahara, Yosuke Miura, Hiroaki Tsurumaki, Kenichiro Hara, Yasuhiko Koga, Noriaki Sunaga, Takuhisa Okada, Hayato Ikota, Takeshi Hisada, Toshitaka Maeno   +17 more
doaj   +1 more source

Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized.
Stephanie Shintani Smith, Sam L. Kaefer, Harsh Duvvuru, Robert C. Kern, Brent A. Senior, Vijay R. Ramakrishnan   +5 more
wiley   +1 more source

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?

Respiratory Medicine Case Reports
The efficacy of mepolizumab as an alternative to glucocorticoids for treating idiopathic chronic eosinophilic pneumonia (ICEP) has been reported. However, various questions remain unanswered, such as the most appropriate dose and dosage interval of ...
Masamitsu Hamakawa, Machiko Arita, Hiroshi Takahashi, Akihiko Amano, Nobuyoshi Hamao, Ayaka Tanaka, Akihiro Ito, Tadashi Ishida   +7 more
doaj   +1 more source

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Allergy, Asthma & Clinical Immunology, 2019
Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the ...
Hector Ortega, Catherine Lemiere, Jean-Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro   +7 more
doaj   +1 more source

Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologics and endoscopic sinus surgery (ESS) treat refractory chronic rhinosinusitis with nasal polyposis (CRSwNP), but direct comparisons are lacking. We synthesized efficacy and subgroup data across randomized controlled trials (RCTs) of biologics and ESS.
Arun Chakravorty, Matthew E. Lin, Rory Lubner, Jess C. Mace, Jeffrey Suh, Jivianne Lee, Marilene Wang, Sarah Wise, Naweed Chowdhury, Zachary M. Soler, Justin Turner, Timothy L. Smith, Myung Sim, Daniel M. Beswick   +13 more
wiley   +1 more source

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Allergy, Asthma & Clinical Immunology
Background Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with ...
Kenneth R. Chapman, Kathryn Cogger, Erin Arthurs, Callahan LaForty, Shane Golden, Bradley Millson, Koyo Usuba, Christopher Licskai   +7 more
doaj   +1 more source

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence

Frontiers in Immunology
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES.
Elvira Mora, María Laura Fox, María Laura Fox, Angelina Lemes, Beatriz Velasco, Jesús María Hernández-Rivas, Jesús María Hernández-Rivas   +6 more
doaj   +1 more source

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

BMC Pulmonary Medicine, 2019
Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance ...
Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +1 more source

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine, 2023
BackgroundHypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage.
Florence Roufosse, Joseph Butterfield, Jonathan Steinfeld, Jane H. Bentley, Robyn von Maltzahn, Namhee Kwon, Linda Nelsen   +6 more
doaj   +1 more source

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Annals of Medicine
Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult ...
Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero   +6 more
doaj   +1 more source